Ranbaxy's US arm has launched an authorised generic version of Pfizer's fixed-dose combination of atorvastatin-amlodipine besylate, Caduet, in the US, as part of an agreement between the two companies.
Ranbaxy said that it is making available the full range of the generic version of Caduet and that the launch further complements its efforts to bring high quality, affordable generic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?